Reporting Manager
Balyasny Asset Management L.P.
Symbol
CTNM
Shares outstanding
30,431,579 shares
Disclosed Ownership
2,312,800 shares
Ownership
7.6%
Form type
SCHEDULE 13G
Filing time
17 Feb 2026, 06:28:31 UTC
Date of event
31 Dec 2025

Sponsored

Quoteable Key Fact

"BALYASNY ASSET MANAGEMENT L.P. disclosed 7.6% ownership in Contineum Therapeutics, Inc. Class A Common Stock, par value $0.001 per share (CTNM) on 31 Dec 2025."

Quick Takeaways

  • BALYASNY ASSET MANAGEMENT L.P. filed SCHEDULE 13G for Contineum Therapeutics, Inc. Class A Common Stock, par value $0.001 per share (CTNM).
  • Disclosed ownership: 7.6%.
  • Date of event: 31 Dec 2025.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 17 Feb 2026, 06:28.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Official SEC Source

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (5)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Balyasny Asset Management L.P. 7.6% 2,312,800 0 2,312,800 /s/ Scott Schroeder Scott Schroeder / Authorized Signatory
BAM GP LLC 7.6% 2,312,800 2,312,800 0 /s/ Scott Schroeder Scott Schroeder / Authorized Signatory
Balyasny Asset Management Holdings LP 7.6% 2,312,800 2,312,800 0 /s/ Scott Schroeder Scott Schroeder / Authorized Signatory
Dames GP LLC 7.6% 2,312,800 2,312,800 0 /s/ Scott Schroeder Scott Schroeder / Authorized Signatory
Dmitry Balyasny 7.6% 2,312,800 2,312,800 0 /s/ Dmitry Balyasny Dmitry Balyasny / Self